“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”

AJMC February 16, 2025
Regina Barragan-Carrillo, MD, Interview by Mary Caffrey

Key Takeaways

• RCC trials are predominantly conducted in high-income countries, neglecting low-income regions where poverty affects outcomes.
• Lack of diversity in clinical trials limits understanding of drug delivery and treatment efficacy in low-income countries.
• Collaborative efforts involving governments, NGOs, and international agencies are needed to fund trials in low-income regions.
• Expanding global trial access enhances treatment efficacy, equity, and scientific understanding, benefiting all populations.
• Current funding cuts threaten global health research progress, exacerbating inequities and hindering international collaboration.

Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world’s poor may become...

Today's Sponsors

Today's Sponsor